Products Exenatide is commercially available as an injectable (Byetta, Bydureon). It was approved in the United States in 2005 as the first agent in the GLP-1 receptor agonist group (Byetta). In many countries, the drug was registered a year later. The long-acting Bydureon Pen was approved in many countries in 2012, with additional approval as … Exenatide
Products Lixisenatide was approved as a subcutaneous solution for injection in the EU in 2012, in the United States in 2016, and in many countries in 2017 (Lyxumia). Lixisenatide is also combined with insulin glargine; see iGlarLixi (Suliqua). Structure and properties Lixisenatide is a peptide and GLP1 analog of 44 amino acids that, like exenatide, … Lixisenatide
Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
Products Dulaglutide was approved as a solution for injection in many countries in 2015 (Trulicity). Structure and properties Dulaglutide (ATC A10BJ05) is a fusion protein consisting of two identical chains linked by disulfide bridges. The chains contain: The GLP-1 analog (sequence segment 7-37), which is 90% the same as the natural GLP-1 segment. It has … Dulaglutide
Products Semaglutide was approved in the US and EU in 2017 and in many countries in 2018 as a solution for injection (Ozempic). The agent is structurally and pharmacologically related to liraglutide (Victoza), which, unlike semaglutide, is injected once daily (both Novo Nordisk). In 2019, tablets containing semaglutide were approved for the first time in … Semaglutide